Is Micron a Good Stock to Buy Now?
Like most of its peers in the semiconductor industry, Micron…
Sell
18
BCYC Quote, Financials, Valuation and Earnings
Last price:
$7.36
Seasonality move
:
-7.12%
Day range:
$7.45 - $7.80
52-week range:
$6.10 - $28.67
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
12.35x
P/B ratio:
0.65x
Volume:
305.6K
Avg. volume:
402.9K
1-year change:
-65.85%
Market cap:
$518.3M
Revenue:
$35.3M
EPS (TTM):
-$2.88
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BCYC
Bicycle Therapeutics PLC
|
$8.7M | -$0.81 | -55.59% | -31.65% | $27.70 |
|
ADAP
Adaptimmune Therapeutics PLC
|
$6.6M | -$0.17 | -92.5% | -8.33% | $1.71 |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | $17.97 |
|
EVAX
Evaxion Biotech AS
|
$60K | -$0.71 | -59.42% | -91.42% | $13.25 |
|
NCNA
NuCana PLC
|
-- | -$0.01 | -- | -99.69% | $104.00 |
|
VRNA
Verona Pharma PLC
|
$53.6M | -$0.03 | -- | -89.84% | $81.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BCYC
Bicycle Therapeutics PLC
|
$7.49 | $27.70 | $518.3M | -- | $0.00 | 0% | 12.35x |
|
ADAP
Adaptimmune Therapeutics PLC
|
$0.24 | $1.71 | $61.7M | -- | $0.00 | 0% | 0.34x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
$1.46 | $17.97 | $3.7M | -- | $0.00 | 0% | 1.52x |
|
EVAX
Evaxion Biotech AS
|
$1.31 | $13.25 | $8.3M | -- | $0.00 | 0% | 0.42x |
|
NCNA
NuCana PLC
|
$0.91 | $104.00 | $5.5M | -- | $0.00 | 0% | -- |
|
VRNA
Verona Pharma PLC
|
$58.30 | $81.00 | $5B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BCYC
Bicycle Therapeutics PLC
|
-- | 1.224 | -- | 13.61x |
|
ADAP
Adaptimmune Therapeutics PLC
|
80.92% | 4.133 | 36.44% | 2.60x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | 1.825 | -- | 1.20x |
|
EVAX
Evaxion Biotech AS
|
-- | -1.937 | -- | 2.80x |
|
NCNA
NuCana PLC
|
-- | 0.371 | -- | -- |
|
VRNA
Verona Pharma PLC
|
37.04% | 0.836 | 3.06% | 10.24x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BCYC
Bicycle Therapeutics PLC
|
-- | -$67.1M | -25.48% | -26.21% | -1426.21% | -$9.8M |
|
ADAP
Adaptimmune Therapeutics PLC
|
-- | -$57.2M | -93.9% | -140.5% | -2197.67% | -$35.4M |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
EVAX
Evaxion Biotech AS
|
-- | -$1.7M | -238.97% | -- | -54.59% | -- |
|
NCNA
NuCana PLC
|
-- | -$1.6M | -- | -- | -- | -$9.3M |
|
VRNA
Verona Pharma PLC
|
$34.6M | -$17.8M | -60.44% | -88.7% | -41.57% | -$29.4M |
Bicycle Therapeutics PLC vs. Competitors
-
Which has Higher Returns BCYC or ADAP?
Adaptimmune Therapeutics PLC has a net margin of -1398.44% compared to Bicycle Therapeutics PLC's net margin of -2303.38%. Bicycle Therapeutics PLC's return on equity of -26.21% beat Adaptimmune Therapeutics PLC's return on equity of -140.5%.
Company Gross Margin Earnings Per Share Invested Capital BCYCBicycle Therapeutics PLC-- -$0.75 $793.1M ADAPAdaptimmune Therapeutics PLC-- -$0.31 $62.1M -
What do Analysts Say About BCYC or ADAP?
Bicycle Therapeutics PLC has a consensus price target of $27.70, signalling upside risk potential of 269.83%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $1.71 which suggests that it could grow by 610.94%. Given that Adaptimmune Therapeutics PLC has higher upside potential than Bicycle Therapeutics PLC, analysts believe Adaptimmune Therapeutics PLC is more attractive than Bicycle Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings BCYCBicycle Therapeutics PLC4 3 0 ADAPAdaptimmune Therapeutics PLC2 3 0 -
Is BCYC or ADAP More Risky?
Bicycle Therapeutics PLC has a beta of 1.398, which suggesting that the stock is 39.825% more volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.845, suggesting its more volatile than the S&P 500 by 184.488%.
-
Which is a Better Dividend Stock BCYC or ADAP?
Bicycle Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicycle Therapeutics PLC pays -- of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCYC or ADAP?
Bicycle Therapeutics PLC quarterly revenues are $3.7M, which are larger than Adaptimmune Therapeutics PLC quarterly revenues of $3.2M. Bicycle Therapeutics PLC's net income of -$51.9M is higher than Adaptimmune Therapeutics PLC's net income of -$74.2M. Notably, Bicycle Therapeutics PLC's price-to-earnings ratio is -- while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics PLC is 12.35x versus 0.34x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCYCBicycle Therapeutics PLC12.35x -- $3.7M -$51.9M ADAPAdaptimmune Therapeutics PLC0.34x -- $3.2M -$74.2M
-
Which has Higher Returns BCYC or BDRX?
Biodexa Pharmaceuticals PLC has a net margin of -1398.44% compared to Bicycle Therapeutics PLC's net margin of --. Bicycle Therapeutics PLC's return on equity of -26.21% beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital BCYCBicycle Therapeutics PLC-- -$0.75 $793.1M BDRXBiodexa Pharmaceuticals PLC-- -- $6M -
What do Analysts Say About BCYC or BDRX?
Bicycle Therapeutics PLC has a consensus price target of $27.70, signalling upside risk potential of 269.83%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.97 which suggests that it could grow by 1139.15%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Bicycle Therapeutics PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Bicycle Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings BCYCBicycle Therapeutics PLC4 3 0 BDRXBiodexa Pharmaceuticals PLC1 0 0 -
Is BCYC or BDRX More Risky?
Bicycle Therapeutics PLC has a beta of 1.398, which suggesting that the stock is 39.825% more volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.705, suggesting its more volatile than the S&P 500 by 70.482%.
-
Which is a Better Dividend Stock BCYC or BDRX?
Bicycle Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicycle Therapeutics PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCYC or BDRX?
Bicycle Therapeutics PLC quarterly revenues are $3.7M, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Bicycle Therapeutics PLC's net income of -$51.9M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Bicycle Therapeutics PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics PLC is 12.35x versus 1.52x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCYCBicycle Therapeutics PLC12.35x -- $3.7M -$51.9M BDRXBiodexa Pharmaceuticals PLC1.52x -- -- --
-
Which has Higher Returns BCYC or EVAX?
Evaxion Biotech AS has a net margin of -1398.44% compared to Bicycle Therapeutics PLC's net margin of -64.14%. Bicycle Therapeutics PLC's return on equity of -26.21% beat Evaxion Biotech AS's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BCYCBicycle Therapeutics PLC-- -$0.75 $793.1M EVAXEvaxion Biotech AS-- -$0.40 $74K -
What do Analysts Say About BCYC or EVAX?
Bicycle Therapeutics PLC has a consensus price target of $27.70, signalling upside risk potential of 269.83%. On the other hand Evaxion Biotech AS has an analysts' consensus of $13.25 which suggests that it could grow by 911.45%. Given that Evaxion Biotech AS has higher upside potential than Bicycle Therapeutics PLC, analysts believe Evaxion Biotech AS is more attractive than Bicycle Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings BCYCBicycle Therapeutics PLC4 3 0 EVAXEvaxion Biotech AS1 0 0 -
Is BCYC or EVAX More Risky?
Bicycle Therapeutics PLC has a beta of 1.398, which suggesting that the stock is 39.825% more volatile than S&P 500. In comparison Evaxion Biotech AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BCYC or EVAX?
Bicycle Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evaxion Biotech AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicycle Therapeutics PLC pays -- of its earnings as a dividend. Evaxion Biotech AS pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCYC or EVAX?
Bicycle Therapeutics PLC quarterly revenues are $3.7M, which are larger than Evaxion Biotech AS quarterly revenues of $3M. Bicycle Therapeutics PLC's net income of -$51.9M is lower than Evaxion Biotech AS's net income of -$1.9M. Notably, Bicycle Therapeutics PLC's price-to-earnings ratio is -- while Evaxion Biotech AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics PLC is 12.35x versus 0.42x for Evaxion Biotech AS. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCYCBicycle Therapeutics PLC12.35x -- $3.7M -$51.9M EVAXEvaxion Biotech AS0.42x -- $3M -$1.9M
-
Which has Higher Returns BCYC or NCNA?
NuCana PLC has a net margin of -1398.44% compared to Bicycle Therapeutics PLC's net margin of --. Bicycle Therapeutics PLC's return on equity of -26.21% beat NuCana PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BCYCBicycle Therapeutics PLC-- -$0.75 $793.1M NCNANuCana PLC-- -$0.32 -- -
What do Analysts Say About BCYC or NCNA?
Bicycle Therapeutics PLC has a consensus price target of $27.70, signalling upside risk potential of 269.83%. On the other hand NuCana PLC has an analysts' consensus of $104.00 which suggests that it could grow by 11366.37%. Given that NuCana PLC has higher upside potential than Bicycle Therapeutics PLC, analysts believe NuCana PLC is more attractive than Bicycle Therapeutics PLC.
Company Buy Ratings Hold Ratings Sell Ratings BCYCBicycle Therapeutics PLC4 3 0 NCNANuCana PLC0 1 0 -
Is BCYC or NCNA More Risky?
Bicycle Therapeutics PLC has a beta of 1.398, which suggesting that the stock is 39.825% more volatile than S&P 500. In comparison NuCana PLC has a beta of 1.464, suggesting its more volatile than the S&P 500 by 46.355%.
-
Which is a Better Dividend Stock BCYC or NCNA?
Bicycle Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicycle Therapeutics PLC pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCYC or NCNA?
Bicycle Therapeutics PLC quarterly revenues are $3.7M, which are larger than NuCana PLC quarterly revenues of --. Bicycle Therapeutics PLC's net income of -$51.9M is lower than NuCana PLC's net income of -$836.1K. Notably, Bicycle Therapeutics PLC's price-to-earnings ratio is -- while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics PLC is 12.35x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCYCBicycle Therapeutics PLC12.35x -- $3.7M -$51.9M NCNANuCana PLC-- -- -- -$836.1K
-
Which has Higher Returns BCYC or VRNA?
Verona Pharma PLC has a net margin of -1398.44% compared to Bicycle Therapeutics PLC's net margin of -92.29%. Bicycle Therapeutics PLC's return on equity of -26.21% beat Verona Pharma PLC's return on equity of -88.7%.
Company Gross Margin Earnings Per Share Invested Capital BCYCBicycle Therapeutics PLC-- -$0.75 $793.1M VRNAVerona Pharma PLC94.44% -$0.40 $324.9M -
What do Analysts Say About BCYC or VRNA?
Bicycle Therapeutics PLC has a consensus price target of $27.70, signalling upside risk potential of 269.83%. On the other hand Verona Pharma PLC has an analysts' consensus of $81.00 which suggests that it could grow by 38.94%. Given that Bicycle Therapeutics PLC has higher upside potential than Verona Pharma PLC, analysts believe Bicycle Therapeutics PLC is more attractive than Verona Pharma PLC.
Company Buy Ratings Hold Ratings Sell Ratings BCYCBicycle Therapeutics PLC4 3 0 VRNAVerona Pharma PLC5 0 0 -
Is BCYC or VRNA More Risky?
Bicycle Therapeutics PLC has a beta of 1.398, which suggesting that the stock is 39.825% more volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.165, suggesting its less volatile than the S&P 500 by 83.527%.
-
Which is a Better Dividend Stock BCYC or VRNA?
Bicycle Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicycle Therapeutics PLC pays -- of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCYC or VRNA?
Bicycle Therapeutics PLC quarterly revenues are $3.7M, which are smaller than Verona Pharma PLC quarterly revenues of $36.7M. Bicycle Therapeutics PLC's net income of -$51.9M is lower than Verona Pharma PLC's net income of -$33.8M. Notably, Bicycle Therapeutics PLC's price-to-earnings ratio is -- while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics PLC is 12.35x versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCYCBicycle Therapeutics PLC12.35x -- $3.7M -$51.9M VRNAVerona Pharma PLC-- -- $36.7M -$33.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Uber Finally on the Path to Consistent Profitability?
After posting massive losses quarter after quarter for years, Uber…
How High Will MSTY Go By 2030?
YieldMax’s MSTR Option Income Strategy ETF (MSTY) is a high-yield…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 31x
Sell
42
Is NVDA Stock a Buy?
Market Cap: $2.5T
P/E Ratio: 36x
Alerts
Buy
91
TORXF alert for Apr 17
Torex Gold Resources [TORXF] is down 2.15% over the past day.
Sell
25
BULZ alert for Apr 17
MicroSectors Solactive FANG & Innov 3X Levd ETN [BULZ] is down 1.92% over the past day.
Sell
44
VIST alert for Apr 17
Vista Energy SAB de CV [VIST] is up 6.93% over the past day.
